105 patents currently held
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Jun 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
15
Ending by 2030
Jun 2027
Next term end
77
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2028 · High confidence
Also notable
Ends Mar 2035 · High confidence
Also notable
Ends May 2034 · High confidence
Self-Assembling Cell Aggregates and Methods of Making Engineered Tissue Using the Same
US 8,241,905
The most cited patent in this portfolio, cited by 140 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2028.
Expandable Vertebral Body Replacement Device and Method
US 9,889,018
Cited by 23 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Monitoring Neurological Functional Status
US 10,448,825
Cited by 15 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2034.
Formerly held, still cited
Notable
Ends Apr 2027 · High confidence
Cited by 58 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Jan 4 to 14, 2027 · next Jan 4
- 5 fees due Feb 6 to 27, 2027 · next Feb 6
- 4 fees due Apr 1 to 22, 2027 · next Apr 1
- 3 fees due May 7 to 21, 2027 · next May 7
- 2 fees due Jun 5 to 10, 2027 · next Jun 5
- 1 fee due Jul 30, 2027The maintenance fee for CD38-NAD+ Regulated Metabolic Axis in Anti-Tumor Immunotherapy (US 11,883,430) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 2 fees due Aug 16 to 27, 2027 · next Aug 16
- 3 fees due Sep 5 to 26, 2027 · next Sep 5
- 1 fee due Oct 23, 2027The maintenance fee for Activated CD26-HIGH Immune Cells and CD26-Negative Immune Cells and Uses Thereof (US 11,963,980) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for T Regulatory (Treg) Cell Transplantation in Osteogenesis Imperfecta (OI) (US 11,975,024) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 5 of the patents on this record were granted since Aug 20, 2026
- 9 terms have ended since Aug 20, 2026
What they patent
The 5 largest of its 77 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Expandable Vertebral Body Replacement Device and Method | 5 in force | to Jan 2036 |
| Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions | 4 in force | to Jul 2028 |
| Compositions and Methods for Treating And/Or Preventing Sepsis And/Or Inflammatory Conditions | 3 in force | to May 2044 |
| Minimally Invasive Subdural Evacuating System | 3 in force | to Sep 2040 |
| Pyrazole Compounds, Compositions and Methods for Treatment of Degenerative Diseases and Disorders | 3 in force | to Mar 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,759,304 | Targeting Complement Factor H for Treatment of Diseases In force · High confidence | In force | High confidence | |
| US 9,212,212 | Targeting Complement Factor H for Treatment of Diseases In force · Medium confidence | In force | Medium confidence | |
| US 8,735,365 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy In force · Medium confidence | In force | Medium confidence | |
| US 8,623,617 | Detecting PAX2 for the Diagnosis of Breast Cancer In force (reinstated) · Medium confidence | In force (reinstated) | Medium confidence | |
| US 8,722,367 | Detecting PAX2 for the Diagnosis of Breast Cancer In force · Medium confidence | In force | Medium confidence | |
| US 8,241,905 | Self-Assembling Cell Aggregates and Methods of Making Engineered Tissue Using the Same In force · High confidence | In force | High confidence | |
| US 8,088,603 | Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions In force · High confidence | In force | High confidence | |
| US 8,569,225 | Targeting Complement Factor H for Treatment of Diseases In force · Medium confidence | In force | Medium confidence | |
| US 8,506,499 | Predicting Atrial Fibrillation Recurrence by Protease and Protease Inhibitor Profiling In force · High confidence | In force | High confidence | |
| US 8,489,186 | Devices and Methods for Treatment of Myocardial Conditions In force · High confidence | In force | High confidence |
Also on record, not counted in the 105: 8 patents in force now held by others · 83 patents ended · 54 applications pending · 122 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.